BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 12, 2012--
Laboratory Corporation of America® Holdings (LabCorp®)
(NYSE: LH) announced today that for the period of September 12, 2012 to
March 11, 2013, its Zero Coupon Convertible Subordinated Notes due 2021
(Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes,
accrue contingent cash interest at a rate of no less than 0.125% of the
average market price of a Zero Coupon Note for the five trading days
ended September 7, 2012, in addition to the continued accrual of the
original issue discount. Contingent cash interest, which the Company has
determined to be approximately $1.48 per Note, will be payable to
holders of the Zero Coupon Notes as of the record date, which is
February 22, 2013. The payment of contingent cash interest is expected
to be made on March 11, 2013.
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500
company, is a pioneer in commercializing new diagnostic technologies and
the first in its industry to embrace genomic testing. With annual
revenues of $5.5 billion in 2011, over 31,000 employees worldwide, and
more than 220,000 clients, LabCorp offers more than 4,000 tests ranging
from routine blood analyses to reproductive genetics to companion
diagnostics. LabCorp furthers its scientific expertise and innovative
clinical testing technology through its LabCorp Specialty Testing Group:
The Center for Molecular Biology and Pathology, National Genetics
Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing,
Litholink Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems,
Inc., Monogram Biosciences, Inc., Colorado Coagulation, and Endocrine
Sciences. LabCorp conducts clinical trials testing through its LabCorp
Clinical Trials division. LabCorp clients include physicians, government
agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our organization, visit
our Web site at: www.labcorp.com.
This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various
important factors, including without limitation, competitive actions in
the marketplace and adverse actions of governmental and other
third-party payors. Actual results could differ materially from
those suggested by these forward-looking statements. Further information
on potential factors that could affect LabCorp’s financial results is
included in the Company’s Form 10-K for the year ended December 31,
2011, and subsequent SEC filings.
Source: Laboratory Corporation of America® Holdings
Laboratory Corporation of America® Holdings
Investor/Media
Contact:
Stephen Anderson, 336-436-5076
www.labcorp.com
